Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  title={Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis},
  author={Lawrence D. Jacobs and D. L. Cookfair and Richard A. Rudick and Robert M. Herndon and John R. Richert and Andres M. Salazar and Jill S. Fischer and Donald E. Goodkin and Carl V. Granger and Jack Simon and John J. Alam and David M. Bartoszak and Dennis Bourdette and Jonathan Braiman and Carol M. Brownscheidle and Michael E. Coats and Stanley L. Cohan and David S. Dougherty and R. P. Kinkel and Michele K. Mass and Frederick E. Munschauer and Roger L. Priore and Patrick Pullicino and Barbara J. Scherokman and Bianca Weinstock-Guttman and Ruth H. Whitham},
  journal={Annals of Neurology},
The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta‐1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple… 

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

It is demonstrated that IFNβ-1a treatment is associated with robust, clinically important beneficial effects on disability progression in relapsing MS patients and post hoc analyses related to disability outcomes using data collected during the double-blind, placebo-controlled phase III clinical trial.

Interferon-beta and disability progression in relapsing-remitting multiple sclerosis

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

It is concluded that patients continuing to use intramuscular interferon beta-1a had less disability and better quality of life compared with patients not currently using intramuuscular Interferon Beta-1A 15 years after randomization into a clinical trial.

Long‐term clinical experience with weekly interferon beta‐1a in relapsing multiple sclerosis

The results confirm the safety and suggest a sustained effectiveness of i.m. IFNβ‐1a therapy in multiple sclerosis patients, and hypothesize the presence of possible predictors of clinical outcome.

Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  • Medicine, Psychology
  • 2001
Treatment with interferon beta-1a did not significantly affect disability progression in this cohort, although significant treatment benefit was observed on exacerbation-related outcomes.

Interferon beta 1a for secondary progressive multiple sclerosis

  • R. Hughes
  • Medicine, Psychology
    Journal of the Neurological Sciences
  • 2003

Recombinant human interferon beta in relapsing–remitting multiple sclerosis: a review of the major clinical trials

  • M. Chofflon
  • Medicine, Biology
    European journal of neurology
  • 2000
The evidence available indicates that optimal results are likely to be achieved with the highest tolerable dosage of IFN‐β, and as inflammatory brain lesions in MS have been shown to exhibit more extensive and early axonal damage than previously suspected, early treatment may be advisable in order to delay disease progression in RRMS.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.



Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.

Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis

High-dose systemic rIFNA might reduce clinical and MRI signs of disease activity in RR MS and should be investigated in larger trials.

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

The design and conduct of a randomized, double-blinded, placebo-controlled, multicenter, phase III study of recombinant interferon beta-1a (IFN-β-1a) as treatment for exacerbating-remitting MS are

[Treatment of multiple sclerosis with interferons].

The clinical use of beta interferon considering the cost and large treatment period, must be cautious, reserving it only for confirmed remitting-relapsing modalities of MS, and there is no clear cut evidence that beta interFERon is useful for chronic-progressive MS.

Intrathecal interferon reduces exacerbations of multiple sclerosis.

Ten patients with multiple sclerosis who were treated with human fibroblast interferon (IFN-B) for 6 months showed a significant reduction in their exacerbation rates compared with their rates before treatment, warrant cautious optimism about the efficacy of intrathecally IFN- B in altering the course of multiple sclerosis.

Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.

A randomized, double-blinded, placebo-controlled, two-year multicenter study demonstrated that natural human fibroblast interferon (interferon beta) administered intrathecally (IT) is effective in

Intrathecal interferon for multiple sclerosis.

Findings show that intrathecal administration of IFN-β is feasible in patients with MS, warrant cautious optimism that intrathletic IFn-β may be effective in altering the course of the disease, and support concepts of a viral or dysimmune cause of MS.

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis

It was concluded that the formulation of a useful clinical trial design must be based on specific guidelines for clinical scales and imaging for which task forces were recommended and subsequently appointed.

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

The results suggest that Cop 1 may be beneficial in patients with the exacerbating-remitting form of multiple sclerosis, but it is emphasized that the study is a preliminary one and the data require confirmation by a more extensive clinical trial.